Status:
COMPLETED
A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Lead Sponsor:
Pfizer
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to find out if SU011248 (sunitinib) provides additional benefit when it is given after treatment with two chemotherapy drugs carboplatin and paclitaxel and also if sunitin...
Eligibility Criteria
Inclusion
- Histologically proven NSCLC
- Stage IIIB (locally advanced with malignant effusion) or Stage IV disease
- No prior therapy for NSCLC
- Evidence of unidimensionally measurable disease
Exclusion
- Previous treatment with systemic chemotherapy for lung cancer
- History of or known brain metastases
- NCI CTCAE Grade 3 hemorrhage within 4 weeks of starting study treatment
- Evidence of hemoptysis within 4 weeks of starting study treatment
- Serious acute or chronic illness or recent history of significant cardiac abnormality
- Previous treatment with anti-angiogenesis agents including thalidomide, or inhibitors of EGFR and PDGFR
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT00113516
Start Date
September 1 2005
End Date
March 1 2009
Last Update
May 18 2010
Active Locations (31)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Los Angeles, California, United States, 90048
2
Pfizer Investigational Site
Newark, Delaware, United States, 19713
3
Pfizer Investigational Site
Newark, Delaware, United States, 19718
4
Pfizer Investigational Site
Wilmington, Delaware, United States, 19899